Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueDepreciation & Amortization - TotalEBITEBITDAEBTEPS (Basic)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Weighted Average)Tax ProvisionsTax RateTax RateWages, Salaries and Other
Others
Ratios

Sunshine Biopharma (SBFM) EBT (2016 - 2026)

Sunshine Biopharma filings provide 13 years of EBT readings, the most recent being $5.5 million for Q4 2025.

  • On a quarterly basis, EBT rose 30.16% to $5.5 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.3 million, a 11.46% increase, with the full-year FY2025 number at $1.3 million, up 11.46% from a year prior.
  • EBT hit $5.5 million in Q4 2025 for Sunshine Biopharma, up from -$1.0 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $5.5 million in Q4 2025 to a low of -$23.3 million in Q4 2022.
  • Median EBT over the past 5 years was -$1.1 million (2023), compared with a mean of -$2.0 million.
  • Biggest five-year swings in EBT: tumbled 6461.84% in 2021 and later skyrocketed 508.23% in 2024.
  • Sunshine Biopharma's EBT stood at $667116.0 in 2021, then crashed by 3589.5% to -$23.3 million in 2022, then skyrocketed by 95.58% to -$1.0 million in 2023, then skyrocketed by 508.23% to $4.2 million in 2024, then surged by 30.16% to $5.5 million in 2025.
  • The last three reported values for EBT were $5.5 million (Q4 2025), -$1.0 million (Q3 2025), and -$2.0 million (Q2 2025) per Business Quant data.